Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The enigmatic role of fungal annexins: the case of Cryptococcus neoformans.

Maryam M, Fu MS, Alanio A, Camacho E, Goncalves DS, Faneuff EE, Grossman NT, Casadevall A, Coelho C.

Microbiology. 2019 Aug;165(8):852-862. doi: 10.1099/mic.0.000815. Epub 2019 May 29.

PMID:
31140968
2.

Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility.

Grossman NT, Casadevall A.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02108-16. doi: 10.1128/AAC.02108-16. Print 2017 Mar. Review.

3.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.

4.

Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system.

Grossman NT, Pham CD, Cleveland AA, Lockhart SR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1030-7. doi: 10.1128/AAC.04613-14. Epub 2014 Dec 1.

5.

Epidemiology of echinocandin resistance in Candida.

Grossman NT, Chiller TM, Lockhart SR.

Curr Fungal Infect Rep. 2014 Dec;8(4):243-248. doi: 10.1007/s12281-014-0209-7. Epub 2014 Sep 21.

6.

Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates.

Lockhart SR, Iqbal N, Harris JR, Grossman NT, DeBess E, Wohrle R, Marsden-Haug N, Vugia DJ.

PLoS One. 2013 Sep 3;8(9):e74737. doi: 10.1371/journal.pone.0074737. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/c7250cbd-4c85-423a-8b09-da596a72f830.

Supplemental Content

Loading ...
Support Center